Zycubo-Copper Histidinate
Zycubo (copper histidinate) is a bioavailable copper replacement therapy approved by the U.S. FDA in January 2026 as the first and only treatment for Menkes disease in pediatric patients. It is a rare X‑linked genetic disorder in which the body cannot absorb or transport copper properly, leading to severe neurodegeneration and early mortality. It is administered […]
Nuzolvence-Zoliflodacin
Nuzolvence (zoliflodacin) is a first-in-class, oral antibacterial agent indicated for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents aged 12 years and older who meet weight requirements. Zoliflodacin belongs to a novel class of spiropyrimidinetrione antibiotics and inhibits bacterial type II topoisomerase enzymes, which are essential for DNA replication in Neisseria gonorrhoeae. This […]
Cardamyst-Etripamil
Cardamyst (etripamil) is a prescription intranasal therapy indicated for the acute conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a rapid-acting calcium channel blocker that slows conduction through the atrioventricular (AV) node, helping terminate abnormal cardiac electrical activity responsible for PSVT. Designed for self-administration at symptom onset, Cardamyst provides a […]
Myqorzo-Aficamten
Myqorzo (aficamten) is a prescription oral therapy indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults to improve functional capacity and reduce symptoms. It is a cardiac myosin inhibitor that binds to the motor protein myosin in the heart muscle, reducing excessive contractile force and decreasing left ventricular outflow tract obstruction that […]
Komzifti-Ziftomenib
Komzifti is an advanced anticancer therapy developed for the treatment of adults with relapsed or refractory Acute Myeloid Leukemia (AML) harboring a susceptible Nucleophosmin 1 (NPM1) mutation. It is specifically indicated for patients who have no satisfactory alternative treatment options, addressing a critical unmet medical need in high-risk AML management. Designed to target the molecular […]
Hyrnuo-Sevabertinib
Hyrnuo (sevabertinib) is an oral targeted therapy used to treat adults with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) that has HER2 (ERBB2) tyrosine kinase domain activating mutations. It is prescribed after patients have received at least one prior systemic therapy. Hyrnuo works by blocking HER2-driven tumor growth and is taken twice […]
Jascayd-Nerandomilast
Jascayd is an orally administered small-molecule therapy indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. It works by inhibiting multiple fibrotic and inflammatory signaling pathways involved in lung tissue scarring, thereby slowing disease progression and preserving pulmonary function. Through targeted modulation of fibroblast activity and reduction of extracellular matrix deposition, Jascayd helps […]
Lynkuet-Elinzanetant
Lynkuet is the first and only dual neurokinin 1 and 3 (NK1/NK3) receptor antagonist approved for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. By blocking NK1 and NK3 receptor signaling in the hypothalamic thermoregulatory center, Lynkuet helps reduce the frequency and severity of hot flashes, both during the day and at […]
Kygevvi-Doxecitine And Doxribtimine
Kygevvi is the first FDA-approved oral therapy for the treatment of Thymidine Kinase 2 Deficiency (TK2d) in adults and pediatric patients with symptom onset at 12 years of age or younger. TK2d is a rare, genetic mitochondrial disorder that leads to progressive muscle weakness and respiratory complications. Kygevvi works by replenishing deoxynucleoside levels to help […]
Wayrilz-Rilzabrutinib
Wayrilz is an oral reversible BTK inhibitor indicated for adults with chronic immune thrombocytopenia (ITP). It works by modulating immune pathways to increase platelet counts and reduce the risk of bleeding, offering a convenient twice-daily oral treatment option.
